Patient prognostic scores and association with survival improvement offered by postoperative radiotherapy for resected IIIA/N2 non‐small cell lung cancer: A population‐based study

Autor: Nan Bi, Xiankai Chen, Yin Li, Hounai Xie, Jianjun Qin, Lei Xu
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
non‐small cell lung cancer
medicine.medical_specialty
Lung Neoplasms
medicine.medical_treatment
Population
patient prognostic scores
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
Port (medical)
Carcinoma
Non-Small-Cell Lung
Internal medicine
medicine
Humans
education
Lung cancer
Lymph node
stage IIIA/N2
Aged
Neoplasm Staging
Retrospective Studies
education.field_of_study
Chemotherapy
postoperative radiation
business.industry
Proportional hazards model
Retrospective cohort study
Original Articles
General Medicine
Prognosis
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Survival Analysis
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
T-stage
Female
Original Article
business
cancer‐specific mortality
Zdroj: Thoracic Cancer, Vol 12, Iss 6, Pp 760-767 (2021)
Thoracic Cancer
ISSN: 1759-7706
1759-7714
Popis: Background Currently, there is no consensus on the role of postoperative adjuvant radiotherapy (PORT) for resected stage IIIA/N2 non‐small cell lung cancer (NSCLC). Our study sought to determine which patients may be able to benefit from PORT, based on a patient prognostic score. Methods A retrospective cohort study was conducted to identify patients diagnosed with IIIA/N2 NSCLC between 1988 and 2016 in the SEER database. Eligible patients were divided into the following two groups: PORT group and non‐PORT group. We classified patient prognostic scores as an ordinal factor and stratified patients based on prognostic scores. A Cox proportional hazards model with propensity score weighting was performed to evaluate cancer‐specific mortality (CSM) between the two groups. Results We identified 7060 eligible patients with IIIA/N2 NSCLC, 2833 (40.1%) in the PORT group and 4227 (59.9%) in the non‐PORT group. Overall, the 10‐year CSM rate in the weighted cohorts was 70.4% in the PORT group, 72.0% in the non‐PORT group, and patients who received PORT had a lower CSM rate (p = 0.001). Compared with the non‐PORT group, significant survival improvements in the PORT group were observed in patients with higher age, grade, T stage and lymph node ratio (LNR), and without chemotherapy. The improved survival of patients receiving PORT was significantly correlated with patient prognostic scores (p
The role of postoperative radiotherapy for IIIA/N2 non‐small cell lung cancer is unclear. Treatments for IIIA/N2 non‐small cell lung cancer should be individualized. Patients who received postoperative radiotherapy had a lower CSM rate. The improved survival of patients receiving PORT was correlated with patient prognostic scores. Prognostic scores and clinical characteristics may be helpful in candidate selection for PORT.
Databáze: OpenAIRE
Externí odkaz: